Medpace ($MEDP) Overstated Book-to-Bill Outlook and Hidden Cancellation Problems Case

Investors can submit applications for the lead plaintiff role.

S.D. Ohio

Court

1:26-cv-00346

Case number

04/22/2025

Class period Start

02/09/2026

Class period End

06/05/2026

Lead Plaintiff motion deadline

$MEDP investors filed a claim against Medpace for telling the market it could reach a 1.15 fourth-quarter book-to-bill ratio while downplaying cancellation problems and concentration in metabolic studies.
After Medpace reported a fourth-quarter 2025 book-to-bill ratio of 1.04 and then said cancellations were elevated again in Q4, $MEDP fell 15.9% on February 10, 2026.
$MEDP investors can join this case to be notified about potential recovery.
Case Details:

Between April 22, 2025 and February 9, 2026, Medpace told investors demand was improving, and it had a reasonable path to a 1.15 book-to-bill ratio in the second half of 2025. Executives emphasised strong request flow, improving funding, lower cancellations, and a broad-based pipeline that supported continued growth.

However, during this period, investors allege Medpace was dealing with cancellation pressure that made the target unrealistic. Medpace allegedly failed to disclose the backlog, and pre-backlog cancellations remained elevated and could push fourth-quarter bookings below the 1.15 level it kept highlighting. The growth was more exposed to metabolic studies and less broad-based than investors were told, and these issues made the company’s bookings outlook and 2026 growth picture too optimistic.

Then, on February 9, 2026, the company revealed a fourth-quarter 2025 net book-to-bill ratio of 1.04, below the 1.15 level it had repeatedly pointed investors toward. $MEDP fell 15.9%, closing at $446.05. 

Additional revelations followed on February 10, 2026, including that cancellations were elevated again in Q4, backlog cancellations were the highest in over a year, and the elevated cancellations were skewed toward metabolic programs. 

By February 10, 2026, shares had dropped to $446.05, representing a total decline of 15.9% over the correction period.

Based on these events, $MEDP investors filed a claim against Medpace, alleging the company:
It overstated the path to a 1.15 book-to-bill ratio.
It downplayed rising cancellations and how those cancellations could cut fourth-quarter bookings.
It caused $MEDP to trade at inflated prices until investors learned the company’s outlook was weaker than described.
Investors argue Medpace misled the market about the reliability of its bookings outlook and the effect of cancellations, causing losses when the truth emerged.

Case Type

US Securities Class Action

Case Status

Lead Plaintiff Submission

Alleged Offence

Misleading Statements,

Fraud,

Failure to Disclose,

Omissions

Suspected Party

Directors,

Management

Security Type

Stocks

Trade Direction

Long

Shock Event Date

02/09/2026

Filing date

04/06/2026

Lead Plaintiff Deadline

06/05/2026

Trusted by industry leaders

Endorsed by top professionals who trust our innovative solutions to drive impactful results.